drugset / Trial / NCT00544180

ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week

NCT00544180

Phase 4 Terminated 7 enrolled Sanofi Procter and Gamble · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the satisfaction of subject with Actonel 35 mg Once a Week in the treatment of post-menopausal osteoporosis. Open, non-controlled, multi-center study.

Timeline

Start
2005-05
Primary completion
2006-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Risedronate Small molecule 35 mg

Indications